

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 15/00</b>	<b>A2</b>	(11) International Publication Number: <b>WO 98/54308</b> (43) International Publication Date: 3 December 1998 (03.12.98)
(21) International Application Number: PCT/GB98/01559 (22) International Filing Date: 28 May 1998 (28.05.98) (30) Priority Data: 9710962.3                      28 May 1997 (28.05.97)                      GB (71) Applicant (for all designated States except US): BIOTICA TECHNOLOGY LIMITED [GB/GB]; 112 Hills Road, Cambridge CB2 1PH (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): LEADLAY, Peter, Francis [GB/GB]; 17 Clarendon Road, Cambridge CB2 2BH (GB). STAUNTON, James [GB/GB]; 29 Porson Road, Cambridge CB2 2ET (GB). KHAW, Lake, Ee [MY/GB]; 79 New Street, Cambridge CB1 2QT (GB). (74) Agents: STUART, Ian et al.; Mewburn Ellis, York House; 23 Kingsway, London WC2B 6HP (GB).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  Published Without international search report and to be republished upon receipt of that report.	

(54) Title: POLYKETIDES AND THEIR SYNTHESIS AND USE

## (57) Abstract

The rapamycin gene cluster is an example of a gene cluster which includes a gene (rapL) leading to the formation of a precursor compound (pipecolic acid, in this case) which is required for inclusion in the larger product (rapamycin) produced by the enzymes encoded by the cluster. We have produced a mutant strain containing a rapamycin gene cluster in which the rapL gene is disabled. The strain does not naturally produce rapamycin but does so if fed with pipecolic acid. By feeding with alternative carboxylic acids we have produced variants of rapamycins. Tests have shown biological activity.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

POLYKETIDES AND THEIR SYNTHESIS AND USE

The present invention relates to polyketides and their synthesis and use. It is particularly, but not exclusively, concerned with variants of rapamycin.

Rapamycin (see Fig. 2) is a lipophilic macrolide, of molecular weight 914, with a 1,2,3-tricarbonyl moiety linked to a pipecolic acid lactone. Sequencing of the putative biosynthetic genes of rapamycin has revealed the presence of three exceptionally large open reading frames encoding the modular polyketide synthase (Schwecke et al., P.N.A.S. 92 (17) 7839-7843 (1995)). On either side of these very large genes are ranged open reading frames which appear to encode enzymes that would be required for rapamycin biosynthesis.

The cluster also contains a novel gene (rapL) whose product is proposed to catalyse the formation of the rapamycin precursor L-pipecolate (2) through the cyclodeamination of L-lysine (1) (Molnar et al., Gene 169, 1-7 (1996)):-



The biosynthesis of rapamycin requires a modular polyketide synthase, which uses a shikimate-derived

- 2 -

starter unit and which carries out a total of fourteen successive cycles of polyketide chain elongation that resemble the steps in fatty acid biosynthesis. L-pipecolic acid is then incorporated into the chain, followed by closure of the macrocyclic ring, and both these steps are believed to be catalyzed by a pipecolate-incorporating enzyme (PIE), the product of the rapP gene. Further site-specific oxidations and O-methylation steps are then required to produce rapamycin.

We have now found that we can genetically engineer an S.hygrosopicus organism in which the (rapL) gene is inactivated. The organism cannot produce rapamycin under normal growth conditions but can do so if fed pipecolate. Furthermore feeding the mutant organism with different substrates leads to the production of variants of rapamycin. The same general method can be applied to other systems which involve a precursor compound which is produced by a gene product, e.g. the very closely related FK506 and immunomycin systems which also involve pipecolate.

Thus according to the present invention in a first aspect there is provided a process of modifying a gene cluster involved in the biosynthesis of a polyketide, said gene cluster including a gene ("the precursor gene") responsible for the production of an enzyme which is responsible for the production of a precursor compound which is incorporated into said polyketide; said process comprising the step of deleting or inactivating said

- 3 -

precursor gene. Suitably said process of deleting or inactivating said precursor gene employs phage-mediated gene replacement. In preferred embodiments of the invention the gene cluster is the gene cluster for the production of rapamycin in S. hygroscopicus and the precursor gene is the rapL gene whose product is responsible for the production of L-pipecolate.

In a second aspect the invention provides a process for producing a polyketide comprising modifying a gene cluster by the process according to the first aspect and expressing the modified gene cluster in the presence of a variant precursor compound which is incorporated so that a variant polyketide is produced. For the rapamycin system, examples of the variant precursor compound include L-proline, L-trans-4-hydroxyproline, L-cis-4-hydroxyproline, L-cis-3-hydroxyproline and trans-3-azabicyclo[3,1,0]hexane-2-carboxylic acid.

In further aspects the invention provides polyketides as producible by the above method, pharmaceuticals comprising such polyketides, and the use of such polyketides in preparing pharmaceutical compositions, e.g. immunosuppressants containing rapamycin variants.

Some embodiments of the invention will now be described in greater detail with reference to the accompanying drawings in which;

Fig. 1 shows a portion of the rapamycin gene cluster, wild type and mutated, and the phage vector used

to perform mutation;

Fig. 2 shows structures of rapamycin and some variants; and

Figs. 3 and 4 illustrate the effects of rapamycin and variants on human lymphoblastoid cell lines.

In order to facilitate the production of variant rapamycins, a chromosomal mutant of S. hygroscopicus was created by phage  $\phi$ C31-mediated gene replacement using the method of Lomovskaya et al. [Microbiology (UK) 1997, 143, 815-883]. A unique BamH I site was found 42bp into the rapL gene (1032bp long). This BamH I site was removed by end-filling with E.coli DNA polymerase I thus creating a frameshift in the rapL gene. A 3 kb EcoR I fragment encompassing the entire rapL gene flanked by rapK and part of the rapM genes respectively was cloned into the phase vector, KC515. The recombinant phage was used to transfect S.hygroscopicus. A double recombination event resulted in the creation of a chromosomal mutant of S.hygroscopicus with a frameshift in rapL. This is summarised in Fig. 1.

#### Materials and Methods

Note: the reader is also referred to L.E. Khaw et al., J. Bacteriol., 180 (4) 809-814 (1998) which is incorporated herein by reference, for both experimental details and discussion of the work and the background thereto.

**Materials.** All molecular biology enzymes and

- 5 -

reagents were from commercial sources. Viomycin was a gift from Pfizer, L-pipecolic acid, L-proline, 3,4-dehydroproline, picolinic acid, pyrrole-2-carboxylic acid, trans 4-hydroxyproline, cis 4-hydroxyproline, cis 3-hydroxyproline and (+)-trans-3-aza-bicyclo [3,1,0]hexane-2-carboxylic acid were obtained from Aldrich Chemical Company.

Bacterial strains, phages and growth conditions

Escherichia coli DH10B (GibcoBRL) was grown in 2x(trypitone-yeast extract) medium as described by Sambrook et al, ("Molecular Cloning", Cold Spring Harbor (1989)). Vector pUC18 was obtained from New England Biolabs. or Sigma Chemical Co. E. coli transformants were selected with 100 mg/ml ampicillin. The rapamycin producer Streptomyces hygroscopicus NRRL 5491 (from ATCC) and its derivatives were maintained on SY agar (Soluble starch 1.5%; yeast extract 0.1%; K<sub>2</sub>HPO<sub>4</sub> 0.1%; MgSO<sub>4</sub> x 7 H<sub>2</sub>O 0.1%; NaCl 0.3%; N-tri[Hydroxymethyl)methyl-2-aminoethanesulfonic acid (Tes) buffer 30 mM, pH7.4; agar 1.5%), and cultivated in Tryptic Soy Broth with 1.0% glucose, 100mM MES pH6.0, supplemented with 10 ug/ml viomycin when required. S.lividans J11326 (D A Hopwood et al: "Genetic Manipulation of Streptomyces: a laboratory manual", The John Innes Foundation, Norwich, England (1985)) was cultivated in YEME (Hopwood et al., 1985) or Tap Water Medium (0.5% glucose; 1% sucrose; 0.5% tryptone; 0.25% yeast extract; 36mg EDTA; pH 7.1).

- 6 -

Liquid cultures were grown at 30°C in Erlenmeyer flasks with shaking at 200-250 rpm. Infection with the ~~atr~~ actinophage KC515 (Hopwood (1985) op. cit. and K. F. Chater in: "The Bacteria" IX (119-158), New York 1986) and its derivative  $\Phi$ rapL (present work) were done on solid DNA medium supplemented with 10mM MgSO<sub>4</sub>, 8mM Ca(NO<sub>3</sub>) and 0.5% glucose (Hopwood et al., 1985).

#### Isolation and in vitro manipulation of DNA

DNA manipulations, PCR and electroporation procedures were carried out as described in Sambrook et al (1989). Total S.hygroscopicus DNA was isolated using the Gibco genomic DNA isolation kit. Southern hybridizations were carried out with probes labelled with digoxigenin using the DIG DNA labelling kit (Boehringer Mannheim). DNA fragments for labelling and subcloning were isolated with the Qiaex (Qiagen) gel extraction kit.

#### Construction of $\Phi$ rapL carrying a frameshift in the rapL gene for homologous recombination in S.hygroscopicus

pUC3EcoRI was constructed by cloning a 3034bp Eco RI fragment (nucleotides 93956 to 96990 of the rap cluster) (T. Schwecke et al., P.N.A.S. 92, 7839-7843 (1995)) encompassing the entire rapL gene flanked by rapK and part of the rapM genes respectively into an Eco RI-cut pUC18 modified vector where the Bam HI site in the polylinker region has been removed. A unique Bam HI site (starting at nucleotide 95036 of the rap cluster) was

- 7 -

found 42bp into the rapL gene (nucleotide 95078 to 94047 of the rap cluster; 1032bp long). Plasmid pUC3Eco RI was digested with Bam HI and the cohesive ends were filled in by treating it with E.coli DNA polymerase I (Klenow fragment). The ligated plasmid DNA was redigested with Bam HI and used to transform E.coli. Ampicillin resistant transformants were selected and their plasmid DNA checked for the removal of the Bam HI site by restriction enzyme analysis. This was confirmed by DNA sequencing. The 3kb insert was excised from the plasmid with Eco RI and the cohesive ends blunt-ended by treatment with E.coli DNA polymerase I (Klenow fragment). The blunt-ended insert was cloned into Pvu II cut phage vector KC515, resulting in  $\Phi\Delta rapL$ .

Protoplasts of S.lividans J11326 were transfected with the phage construct as described by Hopwood et al. (1985). Recombinant phage was identified using PCR analysis. Infection of S.hygroscopicus NRRL 5491 with  $\Phi\Delta rapL$  was done according to Lomovskaya et al (Microbiology, 143, 875-883 (1997)) on DNA plates supplemented with glucose,  $MgSO_4$  and  $Ca(NO_3)_2$ . Lysogens were selected by overlaying the plates with  $50 \mu g ml^{-1}$  (final concentration) viomycin 24 h post-infection. Strains that had undergone a second recombination event deleting the integrated phage were identified by selecting viomycin sensitive isolates after three rounds of non-selective growth and sporulation on SY plates. The insertion and subsequent loss of the phage were

confirmed by genomic Southern hybridizations.

Precursor feeding and fermentation of *S.hygroscopicus*

$\Delta$ RapL

5           Precursor feeding of *S.hygroscopicus*  $\Delta$ RapL was performed routinely in 500 ml flasks containing 100ml of Tryptic Soy Broth with 1.0% glucose, 100mM MES pH6.0, supplemented with the appropriate pipecolic acid analogue, at a final concentration of 1mg/ml.

10       *S.hygroscopicus*  $\Delta$ RapL was also cultivated in 2 l flasks containing 400 ml of chemically-defined media as described by Cheng et al (Appl. Microbiol. Biotechnol. 43, 1096-1098, (1995)). For large scale fermentation, 10  $\mu$ l of spores of *S.hygroscopicus*  $\Delta$ RapL was used to

15       inoculate a 100 ml flask containing 30 ml of Tryptic Soy Broth medium. The flask was incubated on a rotary shaker (300 rpm) at 28°C for 4 days. 4 ml of the first seed culture was transferred to a 2 l flask (second seed culture) containing 400 ml of the medium and incubated on

20       a rotary shaker (300 rpm) at 28°C for 4 days. The second seed culture was transferred to a 20l fermenter containing 15 l of the medium. Trans 4-hydroxyproline was added to the medium aseptically to a final concentration of 1mg/ml. The fermentation was carried

25       out at 28°C for 4 days, with an agitation rate of 500 rpm. The cells were harvested and extracted with twice their volume of methanol overnight.

Purification and analysis of rapamycin and its derivatives

After 3-4 days fermentation mycelia were collected by filtration and extracted with two volumes of methanol at room temperature for 1 h. The crude extracts were analysed by lc-ms using a Finnigan MAT (San Jose, CA) LCQ with a Hewlett-Packard 1100 HPLC. The large scale fermentation was worked up similarly. The crude extract was evaporated to dryness and then purified by flash chromatography (Merck silica gel 60, no. 9385) with acetone/hexane 1/1. The fractions containing rapamycins were further purified by preparative HPLC on a 250 x 20 mm RP18 column (HPLC Technology, Macclesfield, UK) using standard conditions. The 15 l fermentation yielded about 15 mg of pure prolyl-rapamycin and 3 mg of 4-hydroxy-prolyl-26-demethoxy-rapamycin. NMR spectra were determined on a Bruker DRX 500 spectrometer.

Biological activity of rapamycin analogues

Rapamycin induces a specific cell cycle arrest in G1 in the cell line 536, which is a human B lymphocytic line immortalised by Epstein Barr virus infection. The potency of each analogue was compared to that of rapamycin using the 536 cells as a bioassay. The 536 cells (obtained from the human genetic mutant cell repository, Camden, New Jersey, USA) were cultured in Iscoves medium supplemented with 10% fetal calf serum. For bioassay, 536 cells were seeded into 96 well

- 10 -

microtitre plates at 10,000 per well in 100 $\mu$ l of growth medium. Drug stocks of 1mM in DMSO were prepared and further dilutions were made to give a constant final concentration of 0.1% DMSO in growth medium. Control cultures were treated with 0.1% DMSO in growth medium; experimental cultures received a final concentration of  $10^{-7}$ M,  $10^{-8}$ M,  $10^{-9}$ M or  $10^{-10}$ M rapamycin or rapamycin analogue. Each culture was set up in triplicate and replicate plates were labelled with 1 $\mu$ Ci tritiated thymidine (Amersham International, specific activity 70Ci/mM) per well for 3h at either 0h; 24h; or 48h incubation with drugs. At the respective time points the cultures were harvested onto glass fibre paper to trap the DNA following water lysis; free nucleotides were washed away. Radioactivity incorporated into the filter discs / trapped DNA was counted in a Packard scintillation counter using biodegradable scintillation fluid.

## 20 Results

### Characterisation of a frameshift chromosomal mutation in the rapL gene

To confirm that the rapL gene product is indeed involved in the biosynthesis of rapamycin as a precursor feeder, the frameshift chromosomal mutant *S.hygrosopicus*  $\Delta$ RapL was isolated as described in Materials and Methods. This mutation was investigated by Southern blot hybridization using the 3kb EcoRI fragment (93956-96990)

- 11 -

to probe Bgl II/Bam HI digested chromosomal DNA. Analysis of the wild-type *S. hygroscopicus* shows the expected 5.9kb (representing nucleotides 89118-95036) and 2.7kb Bam HI/Bgl II fragments (representing nucleotides 95036-97710) after hybridisation. When chromosomal DNA of *S. hygroscopicus*  $\Delta$ RapL was treated similarly, only a 8.6kb Bam HI/Bgl II fragment (representing nucleotides 89118-97710) was detected, indicating that the Bam HI site at position 95036 has been removed. This was confirmed by PCR analysis. Chromosomal DNA was subjected to PCR using oligonucleotide primers identical to, respectively, the sequences from nucleotide 93950 to 93968; and from 96990 to 97010. The expected 3kb DNA fragment was amplified from wild type DNA and, following BamIII digest, two bands roughly 2kb and 1kb in size were detected. In samples containing *S. hygroscopicus*  $\Delta$ RapL chromosomal DNA the 3kb PCR product amplified was found to be resistant to BamHI digestion.

Precursor feeding of the chromosomal mutant  
*S. hygroscopicus*  $\Delta$ RapL

Growing cultures of the mutant *S. hygroscopicus*  $\Delta$ RapL were fed with different amino acid precursors (table 1). Only the three proline derivatives were found to be incorporated as judged by LC-MS. The main rapamycin derivative in the fermentations apart from prolyl rapamycin is a compound with m/z 908 which could correspond to a hydroxy-rapamycin lacking a methoxy

- 12 -

group. Smaller amounts of a compound with  $m/z$  938 were also detected which would correspond to hydroxy-prolyl-rapamycin. MS-fragmentation experiments as well as the characteristic UV spectra clearly indicated that these compounds are rapamycin derivatives with a hydroxyproline incorporated. In order to get enough material for NMR characterisation we fed hydroxyproline on a large scale to the mutant (15L broth) and isolated 3 mg of the compound with  $m/z$  908 as described in material and methods. The NMR data (table 2) showed the chemical shifts and couplings expected for the hydroxy-proline spin system. The changed chemical shifts for the positions 26 and 27 and the unchanged shifts for positions 38-40 as compared to rapamycin proved that the methoxy group is missing at position 26. MS-fragmentation data (table 3) confirmed these findings. This can be inferred from the loss of the C15-C26-fragment leading to a fragment with  $m/z$  644 for both of the new rapamycin derivatives. Furthermore, the loss of the C28-C42-fragment (322 amu) can be seen for both compounds as well as for rapamycin, indicating that there is no modification in this part of the molecules. The ions at  $m/z$  807 and 777 respectively which are equivalent to the loss of the amino acid (131 amu) confirm the presence of OH-proline. This means that the compound with  $m/z$  938 is 4-hydroxyprolyl-rapamycin.

- 13 -

5

10

15

20

Compound fed	Incorporation	Mass (m/z. M+Na <sup>+</sup> )	Retention time LC-MS (min)	Main Product
L-pipecolic acid	Yes	936	8.84	rapamycin
L-proline	Yes	922	7.99	prolyl- rapamycin
L-trans-4- hydroxy proline	Yes	938/908	5.35/6.29	4-hydroxy- prolyl- rapamycin and 4- hydroxy- prolyl-26- demethoxy- rapamycin
L-cis-4- hydroxyproli ne	Yes	938/908	5.35/6.29	as above
L-cis-3- hydroxyproli ne	Yes	938/908	5.35/6.29	3-hydroxy- prolyl- rapamycin and 3- hydroxy- prolyl-26- demethoxy- rapamycin
picolinic acid	No			
pyrrole-2- carboxylic acid	No			

Table 1

Position	<sup>1</sup> H8 (ppm)	<sup>13</sup> C8 (ppm)
1		171.30
2	5.24	58.17
3	2.65, 1.69	38.48
4	4.38	70.63
5	3.37, 2.94	56.53
26	3.58	not determined
27	3.89	70.63
38	2.93	83.90
39	3.37	73.95
40	1.99, 1.33	31.22
49	3.12	55.68
51	3.39	56.50

Table 2

Rapamycin m/z	4-hydroxyprolylrapamycin m/z	4-hydroxyprolyl-26-demethoxyrapamycin m/z
936	938	908
904	906	876
807 (loss of pipecolate, 129 amu)	807 (los of hydroxyproline, 131 amu)	777 (loss of hydroxyproline, 131 amu)
642	644	644
614	616	586
596	598	568
582	584	554
564	566	536

Table 3

Preparation of trans-3-aza-bicyclo[3.1.0]hexane-2-carboxylic acid rapamycin

A 2 L fermentation of *S.hygroscopicus* ΔRapL fed with (+/-)-trans-3-aza-bicyclo[3.1.0]hexane-2-carboxylic acid

- 15 -

(0.5 mg ml<sup>-1</sup>) was grown for 5 days in TSBGM medium (Khaw et al., (1998) J. Bacteriol. 180, 809-814.). The cells were collected by filtration and extracted with 1 L of methanol at 4°C overnight. High pressure liquid chromatograph-electrospray ionization mass spectrometry (HPLC-ESIMS) analysis of the crude methanol extract was performed at this stage using a Hewlett-Packard 1100 LC attached to a Finnigan-Mat LCQ mass spectrometer. Trans-3-aza-bicyclo[3.1.0]hexane-2-carboxylic acid rapamycin was detected in the fermentation broth.

The methanol extracts were combined and concentrated under reduced pressure. The aqueous residue was diluted with 500 mL of distilled water, and extracted three times with 500 mL of distilled ethyl acetate. The combined ethyl acetate extracts were dried with anhydrous sodium sulphate, and evaporated to dryness. The resulting yellow residue was purified by flash column chromatography on a 150 mm x 30 mm (diameter) silica gel column [Merck 60] eluted isocratically with a 1:1 (v/v) mixture of acetone/hexane.

The fractions were analysed by electrospray mass spectrometry. MS-MS and Ms<sup>n</sup> were used to determine the structure of the new rapamycin in the fractions from the flash silica column.

The fractions containing trans-3-aza-bicyclo[3.1.0]hexane-2-carboxylic acid rapamycin were further purified by reversed-phase preparative HPLC on a 250 x 20 mm (diameter) Prodigy ODS3 column (Phenomenex)

- 16 -

using gradient elution starting at 70/30 (v/v)

~~acetonitrile/water rising linearly to 100% acetonitrile~~  
over 25 minutes. The 2 L fermentation yielded about 4 mg  
of pure trans-3-aza-bicyclo[3.1.0]hexane-2-carboxylic  
5 acid rapamycin.

High resolution MS of trans-3-aza-  
bicyclo[3.1.0]hexane-2-carboxylic acid rapamycin on a  
Bruker BioApex FTICR mass spectrometer using electrospray  
ionisation gave a sodiated molecular ion at m/z  
10 934.52776, which confirmed the molecular formula to be  
 $C_{51}H_{77}NO_{13}$ .

#### Biological activity

The dose response of human lymphoblastoid cell lines  
15 536 was measured. In the experiment shown in Figure 3  
the mean cpm of radiolabelled thymidine incorporated into  
the untreated controls shows that 0-3 h drug exposure had  
no appreciable effect on DNA synthesis up to 100nM of  
rapamycin, prolylrapamycin, or 4-hydroxy-prolyl-26-  
20 demethoxy-rapamycin. This implies that none of the  
compounds were toxic to the 536 cell line. After 24 and  
48 hours (Fig. 4) the 536 cells showed a concentration-  
dependent inhibition of DNA synthesis with an ID50% of  
1nM for rapamycin; and 3nM for prolylrapamycin. 4-  
25 hydroxy-prolyl-26-demethoxy-rapamycin was also inhibitory  
but did not reach 50% at 100nM. Previous experiments  
have shown that rapamycin is a profound inhibitor of G1  
progression in the 536 cell line (Metcalf et al.,

- 17 -

Onco gene 15, 1635-1642 (1997)). This is also suggested in these experiments for the rapamycin analogues, since no significant effect was found at 3h but inhibition was observed once the cell population had time to proceed  
5 through a complete cell cycle (24h) and reach the drug arrest point.

- 18 -

---

CLAIMS:

1. A process of modifying a gene cluster involved in the biosynthesis of a polyketide, said gene cluster including a gene ("the precursor gene") responsible for the production of an enzyme which is responsible for the production of a precursor compound which is incorporated into said polyketide; said process comprising the step of deleting or inactivating said precursor gene.
2. A process according to claim 1 wherein said process of deleting or inactivating said precursor gene employs phage-mediated gene replacement.
3. A process according to claim 1 or claim 2 wherein the gene cluster is the gene cluster for the production of rapamycin in S.hygroscopicus and the precursor gene is the rapL gene whose product is responsible for the production of L-pipecolate.
4. A process for producing a polyketide comprising modifying a gene cluster by the process of claim 1, 2 or 3 and expressing the modified gene cluster to produce polyketide synthase enzymes which act in the presence of a variant precursor compound which is incorporated so that a variant polyketide is produced.

- 19 -

5. A process according to claim 4 as appendant on claim 3 wherein the variant precursor compound is selected from L-proline, L-trans-4-hydroxyproline, L-cis-4-hydroxyproline, L-cis-3-hydroxyproline and trans-3-aza-bicyclo[3,1,0]hexane-2-carboxylic acid.

6. A compound selected from prolyl-rapamycin, 4-hydroxy-propyl rapamycin, 4-hydroxyprolyl-2,6-demethoxy-rapamycin, 3-hydroxy-prolyl-rapamycin 3-hydroxy-prolyl-2,6-demethoxy-rapamycin, and trans-3-aza-bicyclo[3,1,0]hexane-2-carboxylic acid rapamycin.

7. A pharmaceutical composition comprising a compound of claim 6.

8. Use of a compound of claim 6 in the manufacture of an immunosuppressant composition.

9. A modified gene cluster as produced by the process of any of claims 1-3.

10. A vector containing the gene cluster of claim 9.

11. A microorganism containing the gene cluster of claim 9 and capable of expressing it.







Fig 1



Rapamycin



R	R1	
H	OCH <sub>3</sub>	prolylrapamycin
OH	H	4-hydroxyprolyl-26-demethoxy-rapamycin



trans-3-aza-bicyclo(3.1.0)hexane-2-carboxylic acid  
rapamycin





Fig.4 DNA synthesis at 45 - 48h in 536 cells after 48h rapalogue therapy



**THIS PAGE BLANK (USPTO)**




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : C12N 15/52, 15/60, 9/88, C12P 17/14, 17/18, A61K 31/41, C07D 498/18, A61K 31/40 // (C12N 9/88, C12R 1:55) (C07D 498/18, 311:00, 273:00, 209:00)		A3	(11) International Publication Number: <b>WO 98/54308</b>
(21) International Application Number: PCT/GB98/01559		(43) International Publication Date: 3 December 1998 (03.12.98)	
(22) International Filing Date: 28 May 1998 (28.05.98)		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(30) Priority Data: 9710962.3 28 May 1997 (28.05.97) GB		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(71) Applicant (for all designated States except US): BIOTICA TECHNOLOGY LIMITED [GB/GB]; 112 Hills Road, Cambridge CB2 1PH (GB).		(88) Date of publication of the international search report: 8 April 1999 (08.04.99)	
(72) Inventors; and (75) Inventors/Applicants (for US only): LEADLAY, Peter, Francis [GB/GB]; 17 Clarendon Road, Cambridge CB2 2BH (GB). STAUNTON, James [GB/GB]; 29 Porson Road, Cambridge CB2 2ET (GB). KHAW, Lake, Ee [MY/GB]; 79 New Street, Cambridge CB1 2QT (GB).			
(74) Agents: STUART, Ian et al.; Mewburn Ellis, York House, 23 Kingsway, London WC2B 6HP (GB).			

(54) Title: POLYKETIDES AND THEIR SYNTHESIS AND USE

## (57) Abstract

The rapamycin gene cluster is an example of a gene cluster which includes a gene (*rapL*) leading to the formation of a precursor compound (pipecolic acid, in this case) which is required for inclusion in the larger product (rapamycin) produced by the enzymes encoded by the cluster. We have produced a mutant strain containing a rapamycin gene cluster in which the *rapL* gene is disabled. The strain does not naturally produce rapamycin but does so if fed with pipecolic acid. By feeding with alternative carboxylic acids we have produced variants of rapamycins. Tests have shown biological activity.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/01559

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/52 C12N15/60 C12N9/88 C12P17/14 C12P17/18  
A61K31/41 C07D498/18 A61K31/40 //(C12N9/88,C12R1:55).  
(C07D498/18,311:00,273:00,209:00)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DENOYA CD ET AL: "A second branched-chain alpha-keto acid dehydrogenase gene cluster (bkdFGH) from Streptomyces avermitilis: its relationship to avermectin biosynthesis and the construction of a bkdF mutant suitable for the production of novel antiparasitic avermectins." J BACTERIOL, JUN 1995, 177 (12) P3504-11, XP002079427 UNITED STATES	1,4,9-11
Y	see the whole document --- -/--	2,3,5

☒ Further documents are listed in the continuation of box C

☒ Patent family members are listed in annex.

### Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

5 February 1999

Date of mailing of the international search report

15.02.99

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Alfaro Faus, I

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/01559

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	<p>HAFNER-EW-ET-AL: "Branched-chain fatty acid requirement for avermectin production by a mutant of <i>Streptomyces avermitilis</i> lacking branched-chain 2-oxo acid dehydrogenase activity."</p> <p>J ANTIBIOT (TOKYO), MAR 1991, 44 (3) P349-56. XP002079428 JAPAN see the whole document</p>	1.4,9-11
X	<p>TANG L ET AL: "Amino acid catabolism and antibiotic synthesis: valine is a source of precursors for macrolide biosynthesis in <i>Streptomyces ambofaciens</i> and <i>Streptomyces fradiae</i>."</p> <p>J BACTERIOL. OCT 1994, 176 (19) P6107-19, XP002079429 UNITED STATES see the whole document</p>	1.4,9-11
X	<p>DUTTON CJ ET AL: "Novel avermectins produced by mutational biosynthesis."</p> <p>J ANTIBIOT (TOKYO), MAR 1991, 44 (3) P357-65. XP002079430 JAPAN see the whole document</p>	1.4,9-11
Y	<p>LOMOVSKAYA, N. ET AL: "Gene disruption and replacement in the rapamycin-producing <i>Streptomyces hygroscopicus</i> strain ATCC 29253"</p> <p>MICROBIOLOGY.. vol. 143, March 1997, pages 875-883, XP002079431 see abstract see page 881, right-hand column, paragraph 2 - page 882, left-hand column, paragraph 1; figure 3</p>	2
Y	<p>MOLNAR I ET AL: "Organisation of the biosynthetic gene cluster for rapamycin in <i>Streptomyces hygroscopicus</i>: analysis of genes flanking the polyketide synthase" GENE,</p> <p>vol. 169, no. 1, 22 February 1996, page 1-7 XP004042979 see abstract see page 4, left-hand column, paragraph 2 - right-hand column, paragraph 1; figure 1</p>	2,3,5

-/--

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/01559

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No
A	SCHWECKE T ET AL: "The biosynthetic gene cluster for the polyketide immunosuppressant rapamycin." PROC NATL ACAD SCI U S A, AUG 15 1995, 92 (17) P7839-43, XP002079432 UNITED STATES see the whole document ---	2,3,5
A	WO 94 10843 A (SMITHKLINE BEECHAM CORP ;CHAN JAMES AMIGO (US); GERBER ROBERT (US)) 26 May 1994 see page 12, line 21 - page 13, line 8; claims 1-6 ---	4-8
A	EP 0 589 703 A (AMERICAN HOME PROD) 30 March 1994 see claims 1-11 ---	4,5
P,X	KHAW LE ET AL: "Mutational biosynthesis of novel rapamycins by a strain of Streptomyces hygroscopicus NRRL 5491 disrupted in rapL, encoding a putative lysine cyclodeaminase." J BACTERIOL, FEB 1998, 180 (4) P809-14, XP002079433 UNITED STATES see the whole document -----	1-11

# INTERNATIONAL SEARCH REPORT

International application No  
PCT/GB 98/01559

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-5 9-11

process for modifying a precursor gene involved in the polyketide biosynthesis , corresponding method of producing a polyketide with a variant precursor , corresponding modified gene cluster , vector and microorganism

2. Claims: 6-8

Compounds selected from proline derivatives of rapamycin , pharmaceutical composition and use for manufacture of immunosuppressant composition

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/01559

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9410843 A	26-05-1994	AU 5601994 A	08-06-1994
		CN 1089653 A	20-07-1994
		ZA 9308349 A	01-08-1994
EP 0589703 A	30-03-1994	AT 136900 T	15-05-1996
		CA 2106034 A	25-03-1994
		DE 69302249 D	23-05-1996
		DE 69302249 T	19-09-1996
		DK 589703 T	13-05-1996
		ES 2085726 T	01-06-1996
		GR 3020093 T	31-08-1996
		HU 70207 A	28-09-1995
		JP 6192269 A	12-07-1994
		US 5441977 A	15-08-1995